ProMetic Reports Its 2014 Fourth Quarter and Year End Highlights and Financial Results - Seite 2

- Announced the pursuit of a clinical program designed to evaluate the benefits of PBI-4050 in patients affected by the metabolic syndrome and resulting type 2 diabetes;

- Entered into an agreement with a syndicate of underwriters under which the underwriters agreed to buy on a bought deal basis, 15.2 million common shares in the capital of the Corporation, including the overallotment, at a price of $1.90 per share for gross proceeds of $28.8 million;

- Disclosed new preclinical data on PBI-4050 from studies performed by Vanderbilt University in very severe model of accelerated type 2 diabetes where PBI-4050 attenuated the development of diabetic nephropathies in type 2 diabetes;

- Received approval to commence clinical trials for its orally active small molecule lead compound, PBI-4050, in patients suffering from Chronic Kidney Disease following the CTA clearance by Health Canada;

- Received clearance by the FDA for its IND application for its intravenous plasminogen for the treatment of type I plasminogen deficiency;

- Announced the pursuit of Idiopathic Pulmonary Fibrosis as one of its PBI-4050 orphan indications;

- Announced its addition to the S&P/TSX SmallCap Index;

- Secured a follow-on investment from Thomvest Seed Capital Inc. consisting of a $20 million loan;

- Announced the launch of fibrinogen for commercial sales during the fourth quarter of 2014 after its successful scale-up at its Laval based plasma purification facility;

- Completed successfully its PBI-4050 Phase I clinical trial in 40 healthy volunteers where it was found to be safe, very well tolerated without any serious adverse events reported;

- Received a $5.6 million purchase order from Octapharma relating to the purchase of PrioClearTM, a proprietary prion capture resin incorporated in Octapharma's manufacturing process for its solvent/detergent treated plasma product, OctaplasLG®

- Increased its ownership in NantPro following the amendment of its related corporate and commercial agreement with NantPharma LLC providing ProMetic with the effective control of NantPro and a greater portion of the future value and revenues associated with the development and sales of IVIG in the US market;